@_backtableuro's hormone dosing claim, fact-checked

What did @_backtableuro actually say?

Dr. Rachel Rubin, a urologist who specializes in sexual medicine, argued that clinicians routinely start patients on hormone doses so low they produce no meaningful effect. Her core claim: patients who fail on inadequate doses walk away thinking "hormones don't work for me" when the real problem is underdosing. She also called out urologists specifically for instructing patients to apply only a pea-sized amount of vaginal estrogen near the urethra, calling that approach both clinically insufficient and psychologically counterproductive.

Her specific target was the 0.025 mg estradiol patch for systemic therapy and minimal topical estrogen application for genitourinary symptoms. She argued patients need "at least a half a gram or a gram in the vagina twice a week" of vaginal estrogen to restore the acidic vaginal pH that signals tissue recovery. She framed clinician hesitancy as fear-driven, suggesting providers are unconsciously communicating unwarranted cancer concerns to patients through their dosing behavior.

Does the science back this up?

Mostly, yes. The evidence on vaginal estrogen and genitourinary syndrome of menopause (GSM) does support using therapeutically adequate doses, and there is a documented pattern of clinicians underprescribing out of misplaced concern. That said, the framing around dosing thresholds deserves scrutiny.

A 2020 position statement from the Menopause Society (formerly NAMS) confirmed that low-dose vaginal estrogen is effective for GSM and carries minimal systemic absorption, but "low-dose" in that context still means doses calibrated to reach the vaginal epithelium effectively. The clinical literature does not support the idea that a 0.025 mg systemic estradiol patch is universally inadequate. Pinkerton et al. (2017, Menopause) showed that even low-dose patches reduce vasomotor symptoms in some patients. Individual response varies considerably. Rubin's broader point about fear-driven underprescribing, however, is supported. Faubion et al. (2018, Mayo Clinic Proceedings) documented that provider discomfort with hormone therapy, often rooted in a misreading of the 2002 Women's Health Initiative data, has led to widespread undertreatment of menopausal symptoms for over two decades.

What did they get wrong (or right)?

She got the big picture right. The overcorrection after the Women's Health Initiative study is well documented, and patients have genuinely suffered from under-treatment of GSM and vasomotor symptoms. Her criticism of clinicians who treat vaginal estrogen like a hazardous substance is well-founded and backed by evidence.

Where the argument gets imprecise: she implies that the 0.025 mg patch is categorically a "dipping a toe" dose for everyone. That is an overgeneralization. Some patients, particularly those with estrogen sensitivity or specific cardiovascular risk profiles, are appropriately started at lower doses with planned titration. Dosing is not one-size-fits-all, and framing any starting dose as inherently inadequate without clinical context oversimplifies the picture. Her claim about vaginal acidification requiring "at least a half a gram or a gram twice a week" is clinically plausible for restoring vaginal tissue, but the exact gram threshold she cites is not a universally agreed-upon standard across clinical guidelines. The Menopause Society recommends dosing adequate to relieve symptoms, not a fixed weight target.

Her cancer framing is worth addressing directly. She says clinicians who underdose are implicitly communicating fear of causing cancer. The evidence is clear that vaginal estrogen does not carry meaningful cancer risk for most patients. Bhupathiraju et al. (2019, JAMA Internal Medicine) found no increased breast cancer risk with vaginal estrogen use. On that point, she is correct.

What should you actually know?

If you have been told hormone therapy did not work for you, it is worth asking whether you were on a dose that had any real chance of working, and for long enough. GSM symptoms in particular often require weeks to months of consistent use before tissue changes become apparent.

That said, do not interpret this video as a reason to self-adjust your dose or pressure your provider into prescribing more. Dosing decisions depend on your symptom severity, your cardiovascular and cancer history, your route of administration, and how your body responds. The correct move is a structured conversation with a provider who specializes in menopause medicine, not a YouTube-informed demand for a higher dose. The Menopause Society maintains a "menopause practitioner" directory if your current provider is not comfortable managing these therapies. Provider hesitancy around HRT is a real clinical problem. That does not mean maximum doses are appropriate for every patient.